-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Shiyao Group (01093.HK) announced that the phase I/II clinical trial (SYS6055-003) of the SYS6055 injection developed by the Group to treat relapsed/refractory B-cell non-Hodgkin lymphoma has been officially launched at the first research center in China.

Zhitongcaijing·11/06/2026 11:09:34
Listen to the news
Zhitong Finance App News, Shiyao Group (01093.HK) announced that the phase I/II clinical trial (SYS6055-003) of the SYS6055 injection developed by the Group to treat relapsed/refractory B-cell non-Hodgkin lymphoma has been officially launched at the first research center in China.